References
- Tolosa-Vilella C, Ruiz-Ripoll A, Mari-Alfonso B, Naval-Sendra E. Olanzapine-induced agranulocytosis: a case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 411–414
- Duggal HS, Gates C, Pathak PC. Olanzapine-induced neutropenia: mechanism and treatment. J Clin Psychopharmacol 2004; 24: 234–235
- Flynn SW, Altman S, MacEwan GW, Black LL, Greenidge LL, Honer WG. Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J Clin Psychopharmacol 1997; 17: 494–495
- Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999; 354:567.
- Konakanchi R, Grace JJ, Szarowicz R, Pato MT. Olanzapine prolongation of granulocytopenia after clozapine discontinuation. J Clin Psychopharmacol 2000; 20: 703–704
- Teter CJ, Early JJ, Frachtling RJ. Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution. J Clin Psychiatry 2000; 61: 872–873
- Hong X, Wang X. Agranulocytosis and neutropenia with typical and atypical neuroleptics. Am J Psychiatry 2001; 158: 1736–1737
- Sahin A, Cosar B. Prolongation of clozapine-induced leukopenia with olanzapine treatment. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 958–959
- Ener RA, Meglathery SB, Van Decker WA, et al. Serotonin syndrome and other serotonergic disorders. Pain Med 2003; 4: 63–74
- Lane R, Baldwin D. Selective serotonin reuptake inhibitor induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208–221
- Dunkley EJC, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: simple and accurate decision rules for serotonin toxicity. Q J Med 2003; 96: 635–642
- Parker G, Parker K. Which antidepressants flick the switch?. Aust N Z J Psychiatry 2003; 37: 464–468
- le Roux PJ, Coetzee J. Tramadol today. Curr Opin Anaesthesiol 2000; 13: 457–461
- Bode L, Dietrich DE, Stoyloff R, Emrich HM, Ludwig H. Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 1997; 349: 178–179
- Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord 2000; 2: 65–70
- Bode L, Auer A, Dietrich DE, Ludwig H. Borna disease virus in mood disorders and benefit of novel antiviral therapy. Abstract of the 4th International Forum on Mood and Anxiety Disorders, Monte Carlo 2003. Available from URL: http://www.aim-internationalgroup.com/2003/ifmad.
- Bode L, Reckwald P, Severus WE, et al. Borna disease virus-specific circulating immune complexes, antigenemia, and free antibodies: the key marker triplet determining infection and prevailing in severe mood disoders. Mol Psychiatry 2001; 6: 481–491
- Wolff T, Heins G, Pauli G, Burger R, Kurth R. Failure to detect Borna disease virus antigen and RNA in human blood. J Clin Virol 2006; 36: 309–311
- Flower R, Ludwig H. Presence of Borna disease virus (BDV)-specific structural components in human blood plasma. J Clin Virol 2006; 36: 312–313
- Desarkar P, Sinha VK. Lamotrigine-induced severe manic switch. Aust N Z J Psychiatry 2006; 40: 718
- Savas HA, Selek S, Bulbul F, Kaya MC, Savas E. Successful treatment with lamotrigine in bipolar depression: a study from Turkey. Aust N Z J Psychiatry 2006; 40: 498–500